Pancreatic alpha-cell dysfunction in diabetes.

A major, yet poorly understood, feature of type 2 diabetes is the excessive hepatic glucose production and the corresponding insulin resistance leading to fasting hyperglycaemia. The tremendous amount of work done to provide the physiological and molecular mechanisms explaining this impairment has led to the emergence of several consensual hypotheses. Among these, is the increased daily and unregulated plasma glucagon concentration in type 2 diabetic patients. Therefore, studies aiming to understand the physiological regulation of glucagon secretion and the corresponding impairment during diabetes are directly relevant to the treatment of type 2 diabetes. Glucagon secretion by alpha-cells is an immediate response to glucopenia. Abnormal secretion of glucagon and other counterregulatory hormones is a hallmark of type 1 and type 2 diabetes and a major limitation to the use of strong hypoglycaemia agents. A few molecular mechanisms of glucose detection triggering counterregulation and in particular inducing glucagon secretion or suppressing it during hyperglycaemic episodes, have been identified. Such mechanisms are related to those of the insulin secreted beta-cell. The glucose transporter GLUT2 and the K-ATP dependent channel, as well as regulatory mechanisms, involved the central nervous system and the gut-brain hormone GLP-1. Over the last years, glucoincretins have provided promising results for the normalization of plasma glucagon concentration of type 2 diabetic patients, which could partly explain the therapeutic benefits of incretin-related therapy. The underlined mechanisms of GLP-1 regulated glucagon secretion are most likely related to the action of the hormone on the activation of the portal and brain glucose sensors. Certainly, strategies aiming to restore glucose-regulated glucagon secretion are important milestones for the treatment of diabetic patient and the prevention of iatrogenic hypoglycaemia.

[1]  D. Drucker,et al.  Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. , 2001, Diabetes.

[2]  B. Ahrén.  Autonomic regulation of islet hormone secretion – Implications for health and disease , 2000, Diabetologia.

[3]  R. Burcelin.  The incretins: a link between nutrients and well-being , 2005, British Journal of Nutrition.

[4]  R. Burcelin,et al.  Evidence that extrapancreatic GLUT2-dependent glucose sensors control glucagon secretion. , 2001, Diabetes.

[5]  S. Theander,et al.  Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. , 2005, Endocrinology.

[6]  E. Ferrannini,et al.  Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. , 2000, Diabetes.

[7]  R. Rizza,et al.  Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.

[8]  S. Theander,et al.  β-Cell Secretory Products Activate α-Cell ATP-Dependent Potassium Channels to Inhibit Glucagon Release , 2005 .

[9]  A. Baron,et al.  Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics , 1987, Diabetes.

[10]  W. A. Müller,et al.  Studies of pancreatic alpha cell function in normal and diabetic subjects. , 1970, The Journal of clinical investigation.

[11]  R. Unger,et al.  Glucagon physiology and pathophysiology in the light of new advances , 1985, Diabetologia.

[12]  Tanya Hansotia,et al.  Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. , 2004, The Journal of clinical investigation.

[13]  D. Pipeleers,et al.  Differences in adrenergic recognition by pancreatic A and B cells. , 1986, Science.

[14]  G. Grodsky,et al.  Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. , 1974, The Journal of clinical investigation.

[15]  P. Raskin,et al.  Abnormal alpha cell function in human diabetes: the response to oral protein. , 1978, The American journal of medicine.

[16]  K. Herzig,et al.  Parasympathetic Innervation and Function of Endocrine Pancreas Requires the Glial Cell Line–Derived Factor Family Receptor α2 (GFRα2) , 2005 .

[17]  G. Grodsky,et al.  Abnormal secretion of insulin and glucagon by the in vitro perfused pancreas of the genetically diabetic Chinese hamster. , 1974, The Journal of clinical investigation.

[18]  C. Buettger,et al.  Sulfonylurea-binding sites and ATP-sensitive K+ channels in alpha-TC glucagonoma and beta-TC insulinoma cells. , 1993, Diabetes.

[19]  J. Habener,et al.  Insulinotropic Glucagon-Like Peptide I Receptor Expression in Glucagon-Producing α-Cells of the Rat Endocrine Pancreas , 1997, Diabetes.

[20]  Y. Horio,et al.  Somatostatin induces hyperpolarization in pancreatic islet α cells by activating a G protein‐gated K+ channel , 1999, FEBS letters.

[21]  P. Rorsman,et al.  Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism , 1997, Diabetes.

[22]  M. Wheeler,et al.  Targeting of voltage-gated K+ and Ca2+ channels and soluble N-ethylmaleimide-sensitive factor attachment protein receptor proteins to cholesterol-rich lipid rafts in pancreatic alpha-cells: effects on glucagon stimulus-secretion coupling. , 2007, Endocrinology.

[23]  Catherine B. Chan,et al.  Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic alpha-cells. , 2005, The Journal of biological chemistry.

[24]  D. Pipeleers,et al.  Interplay of nutrients and hormones in the regulation of glucagon release. , 1985, Endocrinology.

[25]  P. Raskin,et al.  Effect of Insulin Therapy on the Profiles of Plasma Immunoreactive Glucagon in Juvenile-type and Adult-type Diabetics , 1978, Diabetes.

[26]  J. Foley,et al.  Alpha cell function in health and disease: influence of glucagon-like peptide-1 , 2005, Diabetologia.

[27]  Xiaosong Ma,et al.  ATP-Sensitive K+ Channel–Dependent Regulation of Glucagon Release and Electrical Activity by Glucose in Wild-Type and SUR1−/− Mouse α-Cells , 2004 .

[28]  G. Weir,et al.  Glucagon Secretion from the Perfused Pancreas of Streptozotocin-treated Rats , 1976, Diabetes.

[29]  E. Hooghe-Peters,et al.  Interplay of nutrients and hormones in the regulation of insulin release. , 1985, Endocrinology.

[30]  J. Stock,et al.  Glycemic control in mice with targeted disruption of the glucagon receptor gene. , 2002, Biochemical and biophysical research communications.

[31]  J. Holst,et al.  Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Kahn,et al.  Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. , 2005, The Journal of clinical investigation.

[33]  J. Bryan,et al.  Zinc, Not Insulin, Regulates the Rat α-Cell Response to Hypoglycemia In Vivo , 2007, Diabetes.

[34]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.

[35]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.

[36]  M. J. Charron,et al.  Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia , 2006, Diabetologia.

[37]  S. Theander,et al.  Glucose Stimulates Glucagon Release in Single Rat α-Cells by Mechanisms that Mirror the Stimulus-Secretion Coupling in β-Cells , 2005 .

[38]  Carolyn B Levy,et al.  Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. , 2000, Diabetes.

[39]  Xiaosong Ma,et al.  ATP-sensitive K+ channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1-/- mouse alpha-cells. , 2004, Diabetes.

[40]  P. Rorsman,et al.  Adrenaline Stimulates Glucagon Secretion in Pancreatic A-Cells by Increasing the Ca2+ Current and the Number of Granules Close to the L-Type Ca2+ Channels , 1997, The Journal of general physiology.

[41]  R. Rizza,et al.  Hormonal mechanisms in acute glucose counterregulation: the relative roles of glucagon, epinephrine, norepinephrine, growth hormone, and cortisol. , 1980, Metabolism: clinical and experimental.

[42]  H. Ikegami,et al.  Correlation Between Minimal Secretory Capacity of Pancreatic β-Cells and Stability of Diabetic Control , 1988, Diabetes.

[43]  L. Orci,et al.  New Perspectives on the Microvasculature of the Islets of Langerhans in the Rat , 1982, Diabetes.

[44]  T. McDonald,et al.  Glucagon-like peptide 1 improved glycemic control in type 1 diabetes , 2003, BMC endocrine disorders.

[45]  D. Drucker,et al.  Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. , 1996, Endocrinology.

[46]  M. Brownlee,et al.  Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.

[47]  R. Carr,et al.  Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. , 1998, Journal of medicinal chemistry.

[48]  福田 正博.  Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control , 1988 .

[49]  L. Eliasson,et al.  Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting alpha-cells. , 2000, Diabetes.

[50]  M. J. Charron,et al.  Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. , 2006, Endocrinology.

[51]  B. Ahrén.  GLP-1 and Extra-islet Effects , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[52]  J. Halter,et al.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1984, The Journal of clinical investigation.

[53]  E. Samols,et al.  Retrograde perfusion as a model for testing the relative effects of glucose versus insulin on the A cell. , 1986, The Journal of clinical investigation.

[54]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[55]  B. Wajchenberg,et al.  Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. , 1984, Metabolism: clinical and experimental.

[56]  J. Bryan,et al.  Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. , 2007, Diabetes.

[57]  J. Gromada,et al.  Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. , 2007, Endocrine reviews.

[58]  M. Shichiri,et al.  Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic Alpha cells , 1991, Diabetologia.

[59]  B. Ahrén,et al.  Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. , 1998, Diabetes.

[60]  P. Bennett,et al.  Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. , 1977, The Journal of clinical endocrinology and metabolism.

[61]  Catherine B. Chan,et al.  Glucose-regulated Glucagon Secretion Requires Insulin Receptor Expression in Pancreatic α-Cells* , 2005, Journal of Biological Chemistry.

[62]  A. Niijima,et al.  Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. , 1996, The American journal of physiology.

[63]  S. Theander,et al.  Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. , 2005, Diabetes.

[64]  R. Sorenson,et al.  Structural and Functional Considerations of GABA in Islets of Langerhans: β-Cells and Nerves , 1991, Diabetes.

[65]  R. Unger.  Insulin-Glucagon Relationships in the Defense Against Hypoglycemia , 1983, Diabetes.

[66]  K. Herzig,et al.  Parasympathetic innervation and function of endocrine pancreas requires the glial cell line-derived factor family receptor alpha2 (GFRalpha2). , 2005, Diabetes.

[67]  A. Golay,et al.  Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. , 1987, The Journal of clinical endocrinology and metabolism.

[68]  F. Capani,et al.  Predominant Role of Gluconeogenesis in Increased Hepatic Glucose Production in NIDDM , 1989, Diabetes.

[69]  V. Hruby,et al.  Design and synthesis of glucagon partial agonists and antagonists. , 1986, Biochemistry.

[70]  D. Pipeleers,et al.  Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. , 2001, Diabetes.